Montpellier-based SeqOne, a provider of AI software for Next-Generation Sequencing (NGS) data analysis in oncology and rare diseases, has announced a €20M oversubscribed growth funding round.
The round was led by new investor Supernova Invest, with continued participation from existing investors Elaia, Omnes, and Merieux Equity Partners.
Rémi Spagnol, Investment Director at Supernova Invest, says, “SuperNova Invest is proud to partner with SeqOne, a company at the forefront of genomic analysis innovation. Their impressive growth, cutting-edge technology, and visionary leadership team give us strong conviction in their ability to become a global category leader.”
“The market needs modern, automated, scalable solutions, and SeqOne is exceptionally well-positioned to meet this demand. We are excited to support their journey in revolutionising how genetic data is used to improve patient outcomes and to help them build a true European champion with global reach.”
Capital utilisation
SeqOne has secured new investment to support its goal of becoming a leading provider of NGS data analysis and interpretation for clinical diagnostics in Europe and globally.
The funding will help advance its software platform and meet growing demand for genomic interpretation. The proceeds will also strengthen SeqOne’s financial position and support its long-term collaboration with customers.
SeqOne plans growth in three key areas. The company will expand its international operations, following a threefold increase in customers, reaching 140 laboratories across 22 countries and over 110,000 patient analyses expected in 2025.
It will also strengthen its presence in the US market after launching a dedicated, HIPAA-compliant platform in the first quarter of 2025.
In addition, SeqOne will continue to acquire companies to enhance its technical scope and reach, as shown by its recent acquisition of Life & Soft, which focuses on multi-omics.
Martin Dubuc, CEO of SeqOne, says, “This fundraising is a testament to the incredible work of our team and the transformative potential of our platform in making personalised medicine a reality. We are thrilled to welcome Supernova Invest and are deeply grateful for the continued trust of Elaia, Omnes, and Merieux Equity Partners.”
“This new capital injection not only empowers us to scale our international operations, particularly with our US launch, and to further enhance our technological leadership, but it also fortifies our financial foundations, ensuring our customers can depend on us as a steadfast partner for years to come.”
Dubuc adds, “Our goal is to equip every molecular laboratory with the most advanced, intuitive, and reliable genomic analysis solutions.”
SeqOne: From genome to personalised medicine
SeqOne is a deeptech company focused on advancing personalised medicine. It offers an AI-based platform that supports clinical decisions by helping molecular laboratories analyse genetic data.
This platform is used in areas such as cancer, rare diseases, and multi-omics, including pathogen detection, following recent acquisitions. The company works with 140 laboratories in 22 countries and expects to handle over 110,000 patient analyses in 2025.
SeqOne supports healthcare and biopharmaceutical organisations worldwide and is increasing its activity in the US through partnerships and market expansion.
Earlier this month, the company launched SomaHemato, a haematology analysis tool on its platform. The tool includes a module designed to determine Immunoglobulin Heavy Chain Variable (IGHV) mutational status for Chronic Lymphocytic Leukaemia (CLL).
Brief about the investors
Supernova Invest is a VC firm in Europe managing around €800M in assets. Its portfolio includes more than 80 companies working in cleantech, digital, industrial technologies, and healthcare. For 20 years, Supernova Invest has provided capital, experience, and support across all stages of company growth. The firm collaborates with corporations, research institutions, and co-investors to support its portfolio.
Elaia is a European tech and deep tech investor who supports entrepreneurs from early stages to leadership. For over two decades, Elaia has combined scientific and technological knowledge with operational experience to back startups. Through a joint venture with Lazard, called Lazard Elaia Capital, the firm supports founders at different stages. Elaia has partnered with over 100 startups, including Criteo, Mirakl, Shift Technology, AQEMIA, and Alice & Bob.
Omnes is a private equity firm focused on energy transition, managing over €6.7B in assets. The firm supports partnerships with entrepreneurs across renewable energy, sustainable cities, deeptech, and co-investment. Omnes created the Omnes Foundation to support non-profit organisations working with children and young people in education, health, and social and economic integration.
Mérieux Equity Partners (MxEP) is an investment firm focused on the healthcare sector, managing over €1.5B in assets through Innovation and Buyout strategies. The firm supports companies from startups to established businesses. Based in Lyon and Paris, MxEP invests in European companies with growth and transformation potential. By offering financial and operational resources, MxEP helps businesses develop healthcare products and services aimed at improving patient outcomes.
01
These are the top UK-based PR agencies for startups and scale-ups in 2025